PARG and nonpapillary renal cell carcinoma: Both, overexpression of PARP-1 antagonist, PARG, or the treatment with PARP-1 inhibitors reduced viability and clonogenic potential of ccRCC cell lines and suppressed growth of ccRCC xenograft tumors.